PD-L1 IHC 22C3 pharmDx
Qualitative IHC assay using monoclonal anti–PD-L1 (clone 22C3) to detect PD-L1 protein expression in FFPE tumors and support immunotherapy treatment decisions.
Casandra.ai provides a unified ordering experience so you can request this test directly from the performing lab, without changing your workflow.
Ordering is available where Casandra has an active integration with the performing lab. Labs that offer this test can connect with us to enable digital ordering.
About this test
PD-L1 IHC 22C3 pharmDx is an FDA-approved, qualitative immunohistochemical assay that uses monoclonal mouse anti–PD-L1 (clone 22C3) to detect PD-L1 protein in formalin-fixed, paraffin-embedded tumor tissue. Performed with an automated staining system and standardized scoring (e.g., TPS, CPS), it classifies PD-L1 expression status to help identify patients who may be candidates for PD-1/PD-L1–directed therapies.
Where this test fits
| Indication | Biomarker | Biomarker details | Therapy (Select a therapy to open its FDA-approved testing pathway) |
|---|---|---|---|
| Cervical Cancer | PD-L1 | protein expression | KEYTRUDA |
| Esophageal Squamous Cell Carcinoma (ESCC) | PD-L1 | protein expression | KEYTRUDA |
| Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | PD-L1 | protein expression | KEYTRUDA |
| Head and Neck Squamous Cell Carcinoma (HNSCC) | PD-L1 | protein expression | KEYTRUDA |
| Non-Small Cell Lung Cancer (NSCLC) | PD-L1 | protein expression | KEYTRUDA |
| protein expression [Tumor Proportion Score (TPS) ≥ 50%] | LIBTAYO | ||
| Triple-Negative Breast Cancer (TNBC) | PD-L1 | protein expression | KEYTRUDA |
IVD Manufacturer
Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.
Order this test
If your organization is connected to Casandra, you can place an electronic order forPD-L1 IHC 22C3 pharmDx directly from your existing workflow.
Casandra connects providers, labs, and sponsored programs so that companion diagnostics can be ordered consistently and documented cleanly, regardless of which system you start from.